Publication & Citation Trends
Publications
0 total
Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.
Cited by 0
Semantic Scholar
Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Cited by 0
Semantic Scholar
Abstract 5623: Identification of CGT4255 an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration
Cited by 0
Semantic Scholar
Abstract P4-12-19: Preclinical Characterization of a Novel PI3Kα H1047R Mutant-Selective Inhibitor
Cited by 0
Semantic Scholar
Abstract 4729: The reversible and selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
Cited by 1
Semantic Scholar
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
Cited by 0
Semantic Scholar
Abstract P4-12-16: Identification of CGT4255 an EGFR sparing, ErbB2 clinical development candidate with activity across activating mutations in systemic and CNS tumors
Cited by 0
Semantic Scholar
Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS
Cited by 0
Semantic Scholar
Research Topics
Cancer, Hypoxia, and Metabolism
(8)
Protein Kinase Regulation and GTPase Signaling
(6)
HER2/EGFR in Cancer Research
(4)
Fibroblast Growth Factor Research
(4)
DNA Repair Mechanisms
(3)
Affiliations
Pfizer (United States)
Array BioPharma (United States)
Pfizer (France)
Profectus Biosciences (United States)
Cogent (United Kingdom)